Search research articles
Contact Us
Filters
Showing results (141-150 of 1,622) with videos related to
Page
of 163
Sort By:
Seminars in Oncology
|
August 22, 2000
Weekly paclitaxel in the management of ovarian cancer
M Markman
Cleveland Clinic Journal of Medicine
|
April 26, 2000
The genetics, screening, and treatment of epithelial ovarian cancer: an update
M Markman
Critical Reviews in Oncology/Hematology
|
May 23, 2001
Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer
M Markman
Gynecologic Oncology
|
December 6, 2001
Why study third-, fourth-, fifth-, ...line chemotherapy of ovarian cancer?
M Markman
Cancer Investigation
|
April 9, 2001
Monitoring and improving quality of cancer care: easy to recommend, difficult to accomplish
M Markman
Current Oncology Reports
|
December 21, 2000
Cancer, psychologic factors, and behavior: a complex and controversial relationship
M Markman
Gynecologic Oncology
|
May 17, 2011
Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown
Maurie Markman
Current Oncology Reports
|
January 12, 2011
Commentary: Implications of cancer managed as a "chronic illness"
Maurie Markman
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 15, 2011
Counterpoint: chemosensitivity assays for recurrent ovarian cancer
Maurie Markman
Journal of Oncology Practice
|
September 23, 2010
Standard of care versus standards of care in oncology: a not so subtle distinction
Maurie Markman
Page
of 163
Search research articles
Search
Showing results (141-150 of 1,622) with videos related to
Sort By:
Page
of 163
Seminars in Oncology
|
August 22, 2000
Weekly paclitaxel in the management of ovarian cancer
M Markman
Cleveland Clinic Journal of Medicine
|
April 26, 2000
The genetics, screening, and treatment of epithelial ovarian cancer: an update
M Markman
Critical Reviews in Oncology/Hematology
|
May 23, 2001
Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer
M Markman
Gynecologic Oncology
|
December 6, 2001
Why study third-, fourth-, fifth-, ...line chemotherapy of ovarian cancer?
M Markman
Cancer Investigation
|
April 9, 2001
Monitoring and improving quality of cancer care: easy to recommend, difficult to accomplish
M Markman
Current Oncology Reports
|
December 21, 2000
Cancer, psychologic factors, and behavior: a complex and controversial relationship
M Markman
Gynecologic Oncology
|
May 17, 2011
Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown
Maurie Markman
Current Oncology Reports
|
January 12, 2011
Commentary: Implications of cancer managed as a "chronic illness"
Maurie Markman
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 15, 2011
Counterpoint: chemosensitivity assays for recurrent ovarian cancer
Maurie Markman
Journal of Oncology Practice
|
September 23, 2010
Standard of care versus standards of care in oncology: a not so subtle distinction
Maurie Markman
Page
of 163